Pancreatic cancer drug duo shows durable responses, advancing to Phase 3
TL;DR Summary
A two-drug combo of Tango Therapeutics’ vopimetostat and Revolution Medicines’ daraxonrasib produced durable responses in the large majority of pancreatic cancer patients in an early-stage trial, prompting Tango to advance the approach to a Phase 3 study.
Topics:business#combination-therapy#early-stage-trial#health#pancreatic-cancer#revolution-medicines#tango-therapeutics
- Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate statnews.com
- Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer Yahoo Finance
- ‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response BioSpace
- 🔎 Under the Radar: Tango Stock Climbs on Positive Pancreatic Cancer Data WSJ
- Tango Soars as Study Shows Its Drug Can Help Shrink Tumors Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
2 min
vs 2 min read
Condensed
90%
362 → 37 words
Want the full story? Read the original article
Read on statnews.com